A true New York biotech cluster is coming. It’s just going to take some more disruption to get there.
That was one of the big themes I took home when I recapped our latest Big Apple biotech event, “New York’s Life Science Disruptors,” on Monday. The event, which took place last Thursday, March 6, consisted of a lively series of discussions about the state of biotech in the big city, featuring viewpoints from different key contributors to the life sciences ecosystem: academics/researchers, industry players, and investors. Today, I’m circling back with a slideshow look into what was a fun night on East 29th Street (a big thank you to Hana & LaCruz for the photos).
Once again, a special thanks to our speakers and moderators, our event host Alexandria Real Estate Equities, and our sponsors: Halloran Consulting Group and Guard Dog Brand Development.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler
